Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F23%3AN0000019" target="_blank" >RIV/00023728:_____/23:N0000019 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1136/ard-2022-222784" target="_blank" >https://doi.org/10.1136/ard-2022-222784</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/ard-2022-222784" target="_blank" >10.1136/ard-2022-222784</a>
Alternative languages
Result language
angličtina
Original language name
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Original language description
Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6R alpha antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of the Rheumatic Diseases
ISSN
0003-4967
e-ISSN
1468-2060
Volume of the periodical
82
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
15
Pages from-to
773-787
UT code for WoS article
000840805400001
EID of the result in the Scopus database
2-s2.0-85136491534